Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
Once again, Eli Lilly has suffered a setback trying to find a useful drug to combat Alzheimer’s. Last year, a pair of late-stage trials for an injectable drug called solanezumab failed to meet primary endpoints in patients with mild-to-moderate disease (look here). The results ended hopes of quickly seeking regulatory approval, although another late-stage trial is now under way in patients with mild symptoms. Now, Lilly has ended a mid-stage trial of yet another medication – a beta-amyloid precursor protein site-cleaving enzyme, or BACE, inhibitor – after finding cases of abnormal liver tests. The move is a disappointment because these oral treatments are thought to hold promise, especially after injectables targeting the beta-amyloid protein, which forms brain plaques thought to be responsible for Alzheimer’s, have sputtered.
Help employers find you! Check out all the jobs and post your resume.
Once again, Eli Lilly has suffered a setback trying to find a useful drug to combat Alzheimer’s. Last year, a pair of late-stage trials for an injectable drug called solanezumab failed to meet primary endpoints in patients with mild-to-moderate disease (look here). The results ended hopes of quickly seeking regulatory approval, although another late-stage trial is now under way in patients with mild symptoms. Now, Lilly has ended a mid-stage trial of yet another medication – a beta-amyloid precursor protein site-cleaving enzyme, or BACE, inhibitor – after finding cases of abnormal liver tests. The move is a disappointment because these oral treatments are thought to hold promise, especially after injectables targeting the beta-amyloid protein, which forms brain plaques thought to be responsible for Alzheimer’s, have sputtered.
Help employers find you! Check out all the jobs and post your resume.
